HC PAA SH Volume, page-181

The last cohort of Cancer Trial Patients had failed all standard of care ,,, Phase I is a Safety Profile , plenty of patients who arent or wont be on any other meds...
Plus from 2018 and 2019 there should be plenty of information available to RM ..
PharmAust’s Chief Scientific Officer Dr Richard Mollard commented, “These data from the tablet
reformulation program are very encouraging. We can now continue on to the next step of formally
confirming anticancer activity in target species in clinical trials using a very convenient delivery method
and with a tremendous amount of knowledge of how the drug performs in the body”